This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Mindray Medical International Limited (MR): Today's Featured Health Care Loser

Mindray Medical International (MR) pushed the Health Care sector lower today making it today's featured Health Care loser. The sector as a whole closed the day up 1.4%. By the end of trading, Mindray Medical International fell $1.41 (-4.4%) to $30.48 on heavy volume. Throughout the day, 1.5 million shares of Mindray Medical International exchanged hands as compared to its average daily volume of 439,100 shares. The stock ranged in price between $29.86-$31.62 after having opened the day at $31.31 as compared to the previous trading day's close of $31.89. Other company's within the Health Care sector that declined today were: Theratechnologies (THER), down 59.7%, Rexahn Pharmaceuticals (RNN), down 18.4%, Idera Pharmaceuticals (IDRA), down 16.7%, and K-V Pharmaceutical Company (KV.A), down 15.5%.

Mindray Medical International Limited, through its subsidiary, Shenzhen Mindray, develops, manufactures, and markets medical devices worldwide. It operates in three segments: Patient Monitoring and Life Support Products, In-Vitro Diagnostic Products, and Medical Imaging Systems. Mindray Medical International has a market cap of $3.73 billion and is part of the health services industry. The company has a P/E ratio of 22.1, below the average health services industry P/E ratio of 23.2 and above the S&P 500 P/E ratio of 17.7. Shares are up 24.4% year to date as of the close of trading on Thursday. Currently there are six analysts that rate Mindray Medical International a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates Mindray Medical International as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the positive front, Alexza Pharmaceuticals (ALXA), up 44.9%, Response Genetics (RGDX), up 29.1%, Medgenics (MDGN), up 20.6%, and Geron Corporation (GERN), up 15.4%, were all gainers within the health care sector with Eli Lilly and Company (LLY) being today's featured health care sector winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR (XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care (RXD).

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs